444 related articles for article (PubMed ID: 31450841)
1. Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies.
Alqahtani A; Khan Z; Alloghbi A; Said Ahmed TS; Ashraf M; Hammouda DM
Medicina (Kaunas); 2019 Aug; 55(9):. PubMed ID: 31450841
[TBL] [Abstract][Full Text] [Related]
2. Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma.
Swamy SG; Kameshwar VH; Shubha PB; Looi CY; Shanmugam MK; Arfuso F; Dharmarajan A; Sethi G; Shivananju NS; Bishayee A
Target Oncol; 2017 Feb; 12(1):1-10. PubMed ID: 27510230
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon.
Cervello M; McCubrey JA; Cusimano A; Lampiasi N; Azzolina A; Montalto G
Oncotarget; 2012 Mar; 3(3):236-60. PubMed ID: 22470194
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy of hepatocellular cancer.
Wysocki PJ
Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies.
Bertino G; Demma S; Ardiri A; Proiti M; Gruttadauria S; Toro A; Malaguarnera G; Bertino N; Malaguarnera M; Malaguarnera M; Di Carlo I
Biomed Res Int; 2014; 2014():203693. PubMed ID: 25089265
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of hepatocellular carcinoma.
Aravalli RN; Steer CJ; Cressman EN
Hepatology; 2008 Dec; 48(6):2047-63. PubMed ID: 19003900
[TBL] [Abstract][Full Text] [Related]
8. Systemic therapies in hepatocellular carcinoma.
Wörns MA; Weinmann A; Schuchmann M; Galle PR
Dig Dis; 2009; 27(2):175-88. PubMed ID: 19546557
[TBL] [Abstract][Full Text] [Related]
9. Emerging targeted strategies in advanced hepatocellular carcinoma.
Finn RS
Semin Liver Dis; 2013 Feb; 33 Suppl 1():S11-9. PubMed ID: 23457035
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers.
Wang Y; Deng B
Cancer Metastasis Rev; 2023 Sep; 42(3):629-652. PubMed ID: 36729264
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy for hepatocellular carcinoma.
Spangenberg HC; Thimme R; Blum HE
Nat Rev Gastroenterol Hepatol; 2009 Jul; 6(7):423-32. PubMed ID: 19488072
[TBL] [Abstract][Full Text] [Related]
13. Molecular Genetics and Targeted Therapy in Hepatocellular Carcinoma.
Marks EI; Yee NS
Curr Cancer Drug Targets; 2016; 16(1):53-70. PubMed ID: 26373716
[TBL] [Abstract][Full Text] [Related]
14. Molecular targeted therapy for hepatocellular carcinoma.
Thomas M
J Gastroenterol; 2009; 44 Suppl 19():136-41. PubMed ID: 19148808
[TBL] [Abstract][Full Text] [Related]
15. Goals and targets for personalized therapy for HCC.
Couri T; Pillai A
Hepatol Int; 2019 Mar; 13(2):125-137. PubMed ID: 30600478
[TBL] [Abstract][Full Text] [Related]
16. Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice.
Kudo M
Int J Clin Oncol; 2010 Jun; 15(3):242-55. PubMed ID: 20509038
[TBL] [Abstract][Full Text] [Related]
17. Role of DLC1 tumor suppressor gene and MYC oncogene in pathogenesis of human hepatocellular carcinoma: potential prospects for combined targeted therapeutics (review).
Zimonjic DB; Popescu NC
Int J Oncol; 2012 Aug; 41(2):393-406. PubMed ID: 22580498
[TBL] [Abstract][Full Text] [Related]
18. Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs.
Pez F; Lopez A; Kim M; Wands JR; Caron de Fromentel C; Merle P
J Hepatol; 2013 Nov; 59(5):1107-17. PubMed ID: 23835194
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant therapy for hepatocellular carcinoma: current situation and prospect.
Wang Z; Zhang G; Wu J; Jia M
Drug Discov Ther; 2013 Aug; 7(4):137-43. PubMed ID: 24071575
[TBL] [Abstract][Full Text] [Related]
20. Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs?
Brizzi MP; Pignataro D; Tampellini M; Scagliotti GV; Di Maio M
Expert Rev Anticancer Ther; 2016 Oct; 16(10):1053-62. PubMed ID: 27548441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
